Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INMDNASDAQ:LQDANASDAQ:NPCENASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMDInMode$17.74+0.2%$18.32$14.87▼$21.76$1.23B2.081.16 million shs1.87 million shsLQDALiquidia$14.75-2.3%$15.10$8.26▼$16.81$1.26B0.07936,731 shs1.10 million shsNPCENeuroPace$12.29+3.7%$12.64$5.45▼$15.77$400.16M2.06129,213 shs218,479 shsTNDMTandem Diabetes Care$19.16-0.6%$28.08$17.64▼$53.69$1.28B1.451.48 million shs1.08 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMDInMode0.00%-4.99%-5.45%+6.43%-18.09%LQDALiquidia0.00%-0.20%-2.58%+31.10%+2.31%NPCENeuroPace0.00%-1.41%-8.49%+9.02%-10.23%TNDMTandem Diabetes Care0.00%-4.98%-12.92%-47.71%-45.55%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINMDInMode2.587 of 5 stars3.21.00.00.03.01.71.9LQDALiquidia2.5701 of 5 stars3.60.00.00.02.84.20.6NPCENeuroPace2.106 of 5 stars2.43.00.00.01.84.20.6TNDMTandem Diabetes Care4.4792 of 5 stars4.32.00.04.92.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINMDInMode 2.40Hold$22.2525.42% UpsideLQDALiquidia 3.11Buy$26.6380.51% UpsideNPCENeuroPace 2.80Moderate Buy$15.2023.68% UpsideTNDMTandem Diabetes Care 2.61Moderate Buy$45.38136.82% UpsideCurrent Analyst Ratings BreakdownLatest NPCE, TNDM, LQDA, and INMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025LQDALiquidiaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/20/2025LQDALiquidiaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$30.00 ➝ $34.003/20/2025LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $25.003/20/2025LQDALiquidiaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.003/5/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$19.00 ➝ $20.003/5/2025TNDMTandem Diabetes CareMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$45.00 ➝ $22.003/4/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $24.003/3/2025TNDMTandem Diabetes CareThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$42.00 ➝ $24.003/3/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$38.00 ➝ $22.002/28/2025TNDMTandem Diabetes CareBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$60.00 ➝ $53.002/28/2025TNDMTandem Diabetes CareSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$35.00 ➝ $25.00(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINMDInMode$394.82M3.13$1.71 per share10.40$10.12 per share1.75LQDALiquidia$14.00M89.89N/AN/A$0.73 per share20.21NPCENeuroPace$79.91M5.01N/AN/A$0.79 per share15.56TNDMTandem Diabetes Care$940.20M1.35N/AN/A$4.81 per share3.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINMDInMode$181.27M$2.357.559.75N/A45.91%18.25%16.33%5/1/2025 (Estimated)LQDALiquidia-$78.50M-$1.67N/AN/AN/A-765.38%-163.21%-67.14%5/12/2025 (Estimated)NPCENeuroPace-$32.96M-$0.95N/AN/AN/A-36.74%-205.41%-28.29%5/6/2025 (Estimated)TNDMTandem Diabetes Care-$222.61M-$1.46N/AN/AN/A-14.84%-44.19%-11.99%5/1/2025 (Estimated)Latest NPCE, TNDM, LQDA, and INMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/19/2025Q4 2024LQDALiquidia-$0.38-$0.46-$0.08-$0.46$4.60 million$2.92 million3/4/2025Q4 2024NPCENeuroPace-$0.25-$0.18+$0.07-$0.18$21.14 million$21.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINMDInModeN/AN/AN/AN/AN/ALQDALiquidiaN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINMDInModeN/A10.239.38LQDALiquidiaN/A6.336.33NPCENeuroPace6.035.594.77TNDMTandem Diabetes Care1.292.902.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINMDInMode68.04%LQDALiquidia64.54%NPCENeuroPace78.83%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipINMDInMode6.92%LQDALiquidia30.10%NPCENeuroPace22.20%TNDMTandem Diabetes Care2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINMDInMode48069.56 million64.75 millionOptionableLQDALiquidia5085.30 million59.16 millionOptionableNPCENeuroPace17032.56 million23.22 millionOptionableTNDMTandem Diabetes Care2,60066.47 million64.23 millionOptionableNPCE, TNDM, LQDA, and INMD HeadlinesRecent News About These CompaniesTeacher Retirement System of Texas Acquires Shares of 27,570 Tandem Diabetes Care, Inc. (NASDAQ:TNDM)March 30 at 3:36 AM | marketbeat.comTandem Diabetes Care (TNDM) Down 8.9% Since Last Earnings Report: Can It Rebound?March 28 at 5:58 PM | msn.com3 Reasons to Sell TNDM and 1 Stock to Buy InsteadMarch 26, 2025 | finance.yahoo.comRaymond James Financial Inc. Invests $5.89 Million in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)March 25, 2025 | marketbeat.comStifel Nicolaus Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM)March 24, 2025 | markets.businessinsider.comTandem Diabetes Care Inc (TNDM) Launches Control-IQ+ Technology for Enhanced Diabetes ManagementMarch 21, 2025 | gurufocus.comLake Street Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)March 20, 2025 | markets.businessinsider.comTandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 DiabetesMarch 20, 2025 | finance.yahoo.comTandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with ...March 19, 2025 | gurufocus.comTNDM Stock Gains on the Commercial Launch of Control-IQ+ TechnologyMarch 19, 2025 | zacks.comCharles Schwab Investment Management Inc. Grows Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)March 19, 2025 | marketbeat.comTandem Diabetes Care introduces next-gen automated insulin delivery algorithmMarch 18, 2025 | massdevice.comTandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the ...March 18, 2025 | gurufocus.comPositive Outlook for Tandem Diabetes Care: Buy Rating Affirmed Amid Upcoming Trial ResultsMarch 18, 2025 | tipranks.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by AmundiMarch 17, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Moderate Buy" from AnalystsMarch 17, 2025 | marketbeat.comWealthfront Advisers LLC Buys Shares of 54,263 Tandem Diabetes Care, Inc. (NASDAQ:TNDM)March 16, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Purchases 242,965 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)March 14, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 6.1% Following Insider Buying ActivityMarch 13, 2025 | marketbeat.comOptimistic Buy Rating for Tandem Diabetes Care Amid Attractive Valuation and Growth PotentialMarch 13, 2025 | tipranks.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) COO Acquires $190,948.56 in StockMarch 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNPCE, TNDM, LQDA, and INMD Company DescriptionsInMode NASDAQ:INMD$17.74 +0.04 (+0.23%) Closing price 04:00 PM EasternExtended Trading$17.75 +0.01 (+0.06%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.Liquidia NASDAQ:LQDA$14.75 -0.34 (-2.25%) Closing price 04:00 PM EasternExtended Trading$14.74 -0.01 (-0.03%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.NeuroPace NASDAQ:NPCE$12.29 +0.44 (+3.71%) Closing price 04:00 PM EasternExtended Trading$12.29 0.00 (0.00%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Tandem Diabetes Care NASDAQ:TNDM$19.16 -0.12 (-0.62%) Closing price 04:00 PM EasternExtended Trading$19.14 -0.02 (-0.10%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Casey’s General Stores Insider Buys Shares of This Must-Own Stock U.S. Steel and Nippon Merger: Should Investors Bet on It? MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Lululemon Pulls Back Into Classic Dip-Buying Opportunity Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
